metricas
covid
Buscar en
Acta Otorrinolaringológica Española
Toda la web
Inicio Acta Otorrinolaringológica Española Results of radiotherapy in oropharyngeal carcinomas
Journal Information
Vol. 74. Issue 3.
Pages 137-147 (May - June 2023)
Share
Share
Download PDF
More article options
Visits
1
Vol. 74. Issue 3.
Pages 137-147 (May - June 2023)
Original article
Results of radiotherapy in oropharyngeal carcinomas
Resultados de la radioterapia en los carcinomas de orofaringe
Visits
1
Xavier Leóna,b,c, Núria Farréd, Laura Montezumad, Anna Holgadoa, Rosselin Vásqueza,
Corresponding author
rvasquez@santpau.cat

Corresponding author.
, Eduard Neumanna, Miquel Quera,b
a Servicio de Otorrinolaringología, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
b Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
c UVIC. Universitat Central de Catalunya, Vic, Spain
d Servicio de Oncología Radioterápica, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (6)
Table 1. Characteristics of the patients included in this study.
Table 2. Local recurrence-free survival at 5 years according to different variables analysed.
Table 3. Result of a multivariate analysis considering local recurrence-free survival as the dependent variable.
Table 4. Specific survival at 5 years as a function of different variables analysed.
Table 5. Results of a multivariate analysis considering specific survival as the dependent variable.
Table 6. Summary of the results obtained by different authors including the study period (years), the percentage of patients treated with CT-RT, the percentage of patients with stage III-IV tumours, and the percentage of patients with HPV tumours+·.
Show moreShow less
Additional material (1)
Abstract
Objective

To present the results of radiotherapy treatment in patients with oropharyngeal carcinomas.

Material and methods

Retrospective study of a cohort of 359 patients treated with radiotherapy, including chemo- and bio-radiotherapy, during the period 2000−2019. Information on human papillomavirus (HPV) status was available for 202 patients, of whom 26.2% were HPV-positive.

Results

Five-year local recurrence-free survival was 73.5% (95% CI: 68.8%–78.2%). The variables that were related to local disease control in a multivariate study were the local tumor extension category and the HPV status. Five-year local recurrence-free survival for patients with cT1 tumors was 90.0%, for cT2 88.0%, for cT3 70.6%, and for cT4 42.3%. Five-year local recurrence-free survival for HPV-negative tumors was 67.2% and for HPV-positive tumors 93.3%. Five-year specific-disease survival was 64.4% (95% CI: 59.1%–69.7%). Variables that were related to specific survival in a multivariate study were the patient's general condition, local and regional extent of the tumor, and HPV status.

Conclusions

Five-year local recurrence-free survival of patients with oropharyngeal carcinomas treated with radiotherapy was 73.5%. Variables that were related to local control were local tumor extension and HPV status.

Keywords:
Oropharyngeal carcinoma
Radiotherapy
Chemo-radiotherapy
Bio-radiotherapy
Local control
Specific survival
Resumen
Objetivo

Presentar los resultados del tratamiento con radioterapia en pacientes con carcinomas de orofaringe.

Material y métodos

Estudio retrospectivo de una cohorte de 359 pacientes tratados con radioterapia, incluyendo quimio- y bio-radioterapia, durante el periodo 2000−2019. Se dispuso de información del estatus del virus del papiloma humano (VPH) para 202 pacientes, de los que un 26,2% resultaron VPH-positivos.

Resultados

La supervivencia libre de recidiva local a los 5 años fue del 73,5% (IC 95%: 68,8%–78,2%). Las variables que se relacionaron con el control local de la enfermedad en un estudio multivariante fueron la categoría de extensión local del tumor y el estatus VPH. La supervivencia libre de recidiva local a los 5 años para los pacientes con tumores cT1 fue del 90,0%, para los cT2 del 88,0%, para los cT3 del 70,6%, y para los cT4 del 42,3%. La supervivencia libre de recidiva local a los 5 años para los tumores VPH-negativos fue del 67,2% y para los VPH-positivos del 93,3%. La supervivencia específica a los 5 años fue del 64,4% (IC 95%: 59,1%–69,7%). Las variables que se relacionaron con la supervivencia específica en un estudio multivariante fueron el estado general del paciente, la extensión local y regional del tumor, y el estatus VPH.

Conclusiones

La supervivencia libre de recidiva local a los 5 años de los pacientes con carcinomas de orofaringe tratados con radioterapia fue del 73,5%. Las variables que se relacionaron con el control local fueron la extensión local del tumor y el estatus VPH.

Palabras clave:
Carcinoma de orofaringe
Radioterapia
Quimio-radioterapia
Bio-radioterapia
Control local
Supervivencia específica

Article

These are the options to access the full texts of the publication Acta Otorrinolaringológica Española
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Acta Otorrinolaringológica Española

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos